Navigation Links
Are early testing and drug development the most pressing issues in Alzheimer's care?
Date:8/24/2010

Although a new surge of scientific research has uncovered telltale signs of Alzheimer's disease that show up in brain scans and spinal taps, many questions remain unanswered about the clinical value of early testing and the overall direction of patient care, according to Dr. Kenneth S. Kosik, Harriman Professor of Neuroscience Research at the University of California and co-director of UCSB's Neuroscience Research Institute.

Kosik, also formerly a longtime neurologist at the Brigham and Women's Hospital memory clinic in Boston, cautioned that such "biomarker" tests for Alzheimer's do not address the most devastating issues presented by the disease. Indeed, he said, without substantial reforms in the treatment of Alzheimer's, the advent of early testing may only increase the anxiety of patients and their families.

"Suppose you test positive, then what?" Kosik said in a recent interview. "The test doesn't tell you when you might be likely to get the disease, for example. Patients and families will inevitably have many questions about what lies ahead. Unfortunately, the medical system is not set up to answer them."

In his new book, THE ALZHEIMER'S SOLUTION: HOW TODAY'S CARE IS FAILING MILLIONSAND HOW WE CAN DO BETTER (Prometheus Books, $19) Kosik and co-author Ellen Clegg, a former journalist and science communication specialist at the Broad Institute of MIT and Harvard, provide a bold vision for reforming Alzheimer's disease treatment, and outline an array of simple preventive measures that patients can take to delay the onset of symptoms.

The average time from diagnosis to death in patients with Alzheimer's disease is ten years, Kosik said, a time when interest in the patient's welfare by the medical establishment wanes rapidly. Patients and their families are left in a desperate search for information about treatment, experimental leads and clinical trials, and basic support.

While recent news reports have highlighted stepped-up collaboration among scientists in government agencies, universities, and private industry to develop new Alzheimer's drugs, there is certainly no cure on the immediate horizon. Indeed, the drugs currently on the market are not effective as the disease takes its devastating course. "We have no satisfactory treatment for Alzheimer's disease," Kosik said. "If you have a problem for which neither surgery nor pills will work, then the medical system is really more of an obstacle than a help." He explained that people don't generally know this and they think that if they have a medical problem, they should seek help within the medical system. "It need not work that way," he said.

New ethical guidelines are needed to address how testing is handled and for end-of-life care, Kosik argues. The authors recommend clear discussion of medical wishes at the earliest possible stage among patients, families, and physicians. In his clinical work, Kosik found that many patients say they would rather not go on living than accept an illness that will rob their life of dignity.

The time to act is now, the authors write in THE ALZHEIMER'S SOLUTION. With the aging of nearly 80 million baby boomers, Alzheimer's disease is an impending epidemic. To meet this challenge, Kosik and Clegg propose that a network of one-stop centers should be established to provide expertise and reliable information on a range of topics, including diet, physical and cognitive exercise programs that may help reduce the risk for dementia, and palliative measures to reduce suffering. The centers they describe would take a family-oriented, personalized approach to care and prevention, creating an atmosphere conducive to adult learning, and facilitating personal growth in areas that patients have enjoyed over a lifetime, including the arts, dance, socializing, and a host of other possibilities.


'/>"/>

Contact: Jill Maxick
jmaxick@prometheusbooks.com
800-853-7545
Prometheus Books
Source:Eurekalert  

Related medicine news :

1. Black women with SLE develop cardiovascular disease at early age
2. For teens, early sex and media exposure not linked
3. Scientists receive nearly $11 million to develop radiation countermeasures
4. Less May Be More When Treating Early Hodgkins
5. Eye Disease Affects Nearly One in Three Diabetics
6. Biomarkers Could Spot Alzheimers Disease Early, Studies Suggest
7. Signs of Autism May Show in Early Infancy
8. JCI online early table of contents: August 2, 2010
9. Research defines timeframes, factors to deem early stage lung cancer cured
10. Nearly 1 in 5 Californians report need for mental health services, study finds
11. Millions of Americans in early stages of kidney disease need stroke monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Are early testing and drug development the most pressing issues in Alzheimer's care?
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
Breaking Medicine Technology: